The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has
undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal …

Introduction: The discovery of new actionable oncogenic drivers has led to the development
of effective antineoplastic targeted agents in advanced non-small cell lung cancer (NSCLC) …

Oncogenic driver mutations frequently occur in lung cancer and play role in carcinogenesis.
These mutations are usually associated with distinct clinical and histological features and …

Lung cancer remains the leading cause of cancer-related death in men and women, despite
its constantly declining rates in incidence and mortality in the developed world. The past …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …

Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …

Lung cancer accounts for a quarter of all cancer deaths. Non-small cell lung cancer
(NSCLC) is currently segregated by the presence of actionable driver oncogenes. This …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

In the last decade, major progress in the treatment of advanced non-small-cell lung cancer
has been made through the better understanding of the molecular biology of lung cancer …